
FDA Approves Adrabetadex as First Therapy Shown to Improve Survival in Infantile-Onset Niemann-Pick Disease Type C
Key Takeaways
- FDA approval covers pediatric and adult patients ≥7 kg with infantile-onset NPC and neurologic symptom onset before age 6 years, positioning adrabetadex as the first survival-extending NPC therapy.
- Overall survival evidence leveraged 36 treated patients across studies/expanded access versus matched external controls, showing median survival 8.5 versus 4.9 years and 55% mortality-risk reduction.
The FDA approved Beren Therapeutics' adrabetadex, marketed as Lembaz, to reduce the risk of death in patients with infantile-onset Niemann-Pick disease type C.
The FDA has approved adrabetadex (Lembaz; Beren Therapeutics), an intrathecally administered cyclodextrin-based therapy, to reduce the risk of death in adult and pediatric patients who weigh at least 7 kg and have Niemann-Pick disease type C (NPC) with neurological symptom onset before age 6 years, known as infantile-onset NPC (I-NPC). The decision makes adrabetadex the first NPC therapy shown to extend survival.1,2
Approval was based on an overall survival analysis in which treatment was associated with a 55% reduction in the risk of death compared with matched external controls.1 “As the only NPC medicine to improve survival, LEMBAZ gives children more time to be children,” Elizabeth M. Berry-Kravis, MD, PhD, professor of pediatrics and neurological sciences at Rush University Medical Center and lead investigator for the expanded access program, said in a statement.2
Survival Data and Regulatory Pathway
The FDA’s review included 36 patients with I-NPC treated across 3 clinical studies and an expanded access program, compared with a matched external control group that the agency deemed the adequate and well-controlled study supporting approval.1,2 Median survival was 8.5 years among treated patients vs 4.9 years among controls, and the benefit was observed regardless of concomitant miglustat (used off-label in NPC).1 Adrabetadex received Breakthrough Therapy designation, and Beren received a priority review voucher with the approval.1,2
Safety and Monitoring
Adrabetadex, given by a trained provider via intrathecal injection every 2 weeks, carries a boxed warning for hearing impairment, including permanent hearing loss ranging from mild to profound, which has occurred in some patients with normal pretreatment hearing.1,2 Whether continued dosing or dose reduction affects further loss is unknown. Baseline testing includes pure tone audiometry, speech recognition, and tympanometry, and dose titration is guided by repeat evaluations 1 to 2 weeks after each dose at each level. Ataxia and fatigue, typically in the days after dosing, have also occurred, including cases requiring hospitalization. Adverse reactions in at least 25% of trial participants included hearing impairment, ataxia, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough.2
Clinical Context
NPC is an autosomal recessive lysosomal storage disorder caused by pathogenic variants in NPC1 or NPC2 that impair intracellular cholesterol and lipid trafficking, leading to accumulation particularly in the brain.1,3 The FDA estimates it affects approximately 1 in 150,000 people.1 According to Beren, approximately half of US patients, roughly 475 children, have I-NPC, with a mean age at death of approximately 5.6 years for early infantile onset (before age 2) and 13.4 years for late infantile onset (age 2 to younger than 6).2
In September 2024, the FDA approved arimoclomol (Miplyffa; Zevra Therapeutics), used with miglustat, for patients 2 years and older, and levacetylleucine (Aqneursa; IntraBio) for patients weighing at least 15 kg.3 Neither has been shown to reduce mortality, and their age and weight restrictions limit use in the youngest, most severely affected patients.1
Mechanism and Development History
Adrabetadex is a formulation of 2-hydroxypropyl-β-cyclodextrin (HPβCD), which Beren says mobilizes cholesterol trapped within neurons, compensating for defective NPC protein function.2 Because cyclodextrin does not readily cross the blood-brain barrier, it is delivered intrathecally. In an NIH-led, open-label phase 1/2a trial, 14 participants aged 4 to 23 years with NPC1 received monthly intrathecal HPβCD for 12 to 18 months; treatment slowed neurological progression vs a natural history cohort, and hearing loss emerged as an expected adverse effect.4
REFERENCES
1. FDA approves first drug shown to help patients with infantile-onset niemann-pick disease type c live longer. News release. FDA. November 17, 2026. Accessed November 17, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer
2. Beren Therapeutics announces U.S. FDA approval of LEMBAZ (adrabetadex), first & only medicine to improve survival in infantile-onset niemann-pick disease type c. News release. Beren Therapeutics. November 17, 2026. Accessed November 17, 2026. https://www.businesswire.com/news/home/20261116327767/en/
3. Rodriguez-Gil JL, Smith WE, Chang IJ, Mendelsohn BA; ACMG Therapeutics Committee5∗documents@acmg.net. Arimoclomol and levacetylleucine for the treatment of neurologic manifestations of Niemann-Pick disease type C: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG). Genet Med Open. 2025;3:103462. Published 2025 Dec 23. doi:10.1016/j.gimo.2025.103462
4. Ory DS, Ottinger EA, Farhat NY, et al. Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial. Lancet. 2017;390(10104):1758-1768. doi:10.1016/S0140-6736(17)31465-4
Related to this article








